Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 35516 | 96 | 46.5 | 86% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 10 | 3 | IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL | 134299 |
| 741 | 2 | ANTIGEN PRESENTATION//IMMUNOLOGY//ANTIGEN PROCESSING | 12555 |
| 35516 | 1 | BIFUNCTIONAL PEPTIDE INHIBITOR//TYKESON MS//PROTEOLIPID PEPTIDE | 96 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | BIFUNCTIONAL PEPTIDE INHIBITOR | authKW | 1635836 | 6% | 86% | 6 |
| 2 | TYKESON MS | address | 1197467 | 8% | 47% | 8 |
| 3 | PROTEOLIPID PEPTIDE | authKW | 636159 | 2% | 100% | 2 |
| 4 | RECOMBINANT T CELL RECEPTOR LIGAND RTL | authKW | 636159 | 2% | 100% | 2 |
| 5 | SOLUBLE ANTIGEN ARRAY | authKW | 636159 | 2% | 100% | 2 |
| 6 | TYKESON MULTIPLE SCLEROSIS | address | 572541 | 3% | 60% | 3 |
| 7 | NEUROIMMUNOL TYKESON MULTIPLE SCLEROSIS | address | 424105 | 2% | 67% | 2 |
| 8 | AROMATIC AMINO ACID RECEPTOR | authKW | 318080 | 1% | 100% | 1 |
| 9 | AST VAC2 | authKW | 318080 | 1% | 100% | 1 |
| 10 | ATX MS 1467 | authKW | 318080 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Immunology | 877 | 46% | 0% | 44 |
| 2 | Pharmacology & Pharmacy | 79 | 19% | 0% | 18 |
| 3 | Medicine, Research & Experimental | 61 | 10% | 0% | 10 |
| 4 | Cell & Tissue Engineering | 45 | 2% | 0% | 2 |
| 5 | Neurosciences | 43 | 15% | 0% | 14 |
| 6 | Materials Science, Biomaterials | 29 | 3% | 0% | 3 |
| 7 | Chemistry, Medicinal | 22 | 5% | 0% | 5 |
| 8 | Biochemistry & Molecular Biology | 18 | 16% | 0% | 15 |
| 9 | Engineering, Biomedical | 10 | 3% | 0% | 3 |
| 10 | Biochemical Research Methods | 9 | 4% | 0% | 4 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | TYKESON MS | 1197467 | 8% | 47% | 8 |
| 2 | TYKESON MULTIPLE SCLEROSIS | 572541 | 3% | 60% | 3 |
| 3 | NEUROIMMUNOL TYKESON MULTIPLE SCLEROSIS | 424105 | 2% | 67% | 2 |
| 4 | BIORAD S INC | 318080 | 1% | 100% | 1 |
| 5 | MOL INTEGRAT PHYSIOL MOL GENET IMMUNOL | 318080 | 1% | 100% | 1 |
| 6 | NEUROL L219 | 318080 | 1% | 100% | 1 |
| 7 | NEUROL MOL GENET IMMUNOL | 318080 | 1% | 100% | 1 |
| 8 | PEDIT INFECT DIS | 318080 | 1% | 100% | 1 |
| 9 | SERV RD31 | 318080 | 1% | 100% | 1 |
| 10 | THER EUT PARTICLES BIOMAT TECHNOL | 318080 | 1% | 100% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT | 1746 | 1% | 1% | 1 |
| 2 | MOLECULAR PHARMACEUTICS | 1612 | 4% | 0% | 4 |
| 3 | JOURNAL OF IMMUNOLOGY | 1162 | 15% | 0% | 14 |
| 4 | AAPS JOURNAL | 1122 | 2% | 0% | 2 |
| 5 | METABOLIC BRAIN DISEASE | 894 | 2% | 0% | 2 |
| 6 | JOURNAL OF NEUROIMMUNE PHARMACOLOGY | 514 | 1% | 0% | 1 |
| 7 | CLINICAL IMMUNOLOGY | 473 | 2% | 0% | 2 |
| 8 | STEM CELLS TRANSLATIONAL MEDICINE | 465 | 1% | 0% | 1 |
| 9 | REVIEWS IN THE NEUROSCIENCES | 461 | 1% | 0% | 1 |
| 10 | IMMUNOTHERAPY | 440 | 1% | 0% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | SINHA, S , MILLER, L , SUBRAMANIAN, S , MCCARTY, OJT , PROCTOR, T , MEZA-ROMERO, R , HUAN, JY , BURROWS, GG , VANDENBARK, AA , OFFNER, H , (2010) BINDING OF RECOMBINANT T CELL RECEPTOR LIGANDS (RTL) TO ANTIGEN PRESENTING CELLS PREVENTS UPREGULATION OF CD11B AND INHIBITS T CELL ACTIVATION AND TRANSFER OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS.JOURNAL OF NEUROIMMUNOLOGY. VOL. 225. ISSUE 1-2. P. 52-61 | 14 | 67% | 7 |
| 2 | BURROWS, GG , MEZA-ROMERO, R , HUAN, JY , SINHA, S , MOONEY, JL , VANDENBARK, AA , OFFNER, H , (2012) GILT REQUIRED FOR RTL550-CYS-MOG TO TREAT EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS.METABOLIC BRAIN DISEASE. VOL. 27. ISSUE 2. P. 143-149 | 13 | 54% | 3 |
| 3 | HARTWELL, BL , HALL, AS , SWAFFORD, D , SULLIVAN, BP , GARZA, A , SESTAK, JO , NORTHRUP, L , BERKLAND, C , (2016) MOLECULAR DYNAMICS OF MULTIVALENT SOLUBLE ANTIGEN ARRAYS SUPPORT A TWO-SIGNAL CO-DELIVERY MECHANISM IN THE TREATMENT OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS.MOLECULAR PHARMACEUTICS. VOL. 13. ISSUE 2. P. 330 -343 | 18 | 32% | 0 |
| 4 | OFFNER, H , SINHA, S , BURROWS, GG , FERRO, AJ , VANDENBARK, AA , (2011) RTL THERAPY FOR MULTIPLE SCLEROSIS: A PHASE I CLINICAL STUDY.JOURNAL OF NEUROIMMUNOLOGY. VOL. 231. ISSUE 1-2. P. 7-14 | 11 | 55% | 7 |
| 5 | SINHA, S , SUBRAMANIAN, S , EMERSON-WEBBER, A , LINDNER, M , BURROWS, GG , GRAFE, M , LININGTON, C , VANDENBARK, AA , BERNARD, CCA , OFFNER, H , (2010) RECOMBINANT TCR LIGAND REVERSES CLINICAL SIGNS AND CNS DAMAGE OF EAE INDUCED BY RECOMBINANT HUMAN MOG.JOURNAL OF NEUROIMMUNE PHARMACOLOGY. VOL. 5. ISSUE 2. P. 231 -239 | 10 | 56% | 4 |
| 6 | SINHA, S , SUBRAMANIAN, S , MILLER, L , PROCTOR, TM , ROBERTS, C , BURROWS, GG , VANDENBARK, AA , OFFNER, H , (2009) CYTOKINE SWITCH AND BYSTANDER SUPPRESSION OF AUTOIMMUNE RESPONSES TO MULTIPLE ANTIGENS IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY A SINGLE RECOMBINANT T-CELL RECEPTOR LIGAND.JOURNAL OF NEUROSCIENCE. VOL. 29. ISSUE 12. P. 3816-3823 | 11 | 50% | 9 |
| 7 | CLEMENTE-CASARES, X , TSAI, S , YANG, Y , SANTAMARIA, P , (2011) PEPTIDE-MHC-BASED NANOVACCINES FOR THE TREATMENT OF AUTOIMMUNITY: A "ONE SIZE FITS ALL" APPROACH?.JOURNAL OF MOLECULAR MEDICINE-JMM. VOL. 89. ISSUE 8. P. 733-742 | 17 | 30% | 7 |
| 8 | HUAN, J , MEZA-ROMERO, R , MOONEY, JL , VANDENBARK, AA , OFFNER, H , BURROWS, GG , (2011) SINGLE-CHAIN RECOMBINANT HLA-DQ2.5/PEPTIDE MOLECULES BLOCK ALPHA 2-GLIADIN-SPECIFIC PATHOGENIC CD4(+) T-CELL PROLIFERATION AND ATTENUATE PRODUCTION OF INFLAMMATORY CYTOKINES: A POTENTIAL THERAPY FOR CELIAC DISEASE.MUCOSAL IMMUNOLOGY. VOL. 4. ISSUE 1. P. 112-120 | 14 | 29% | 9 |
| 9 | STEWART, J , BADAWI, AH , KIPTOO, P , SIAHAAN, TJ , (2015) A VACCINE-LIKE ADMINISTRATION OF PLP-PEG-B7AP AND MOG-PEG-B7AP TO CONTROL EAE IN RELAPSE-REMISSION AND CHRONIC PROGRESSIVE ANIMAL MODELS OF MULTIPLE SCLEROSIS: BIFUNCTIONAL PEPTIDE INHIBITORS AS PEPTIDE-BASED THERAPEUTIC VACCINES.CHIMICA OGGI-CHEMISTRY TODAY. VOL. 33. ISSUE 2. P. 41 -47 | 11 | 34% | 0 |
| 10 | SINHA, S , MILLER, LM , SUBRAMANIAN, S , BURROWS, GG , VANDENBARK, AA , OFFNER, H , (2011) RTL551 TREATMENT OF EAE REDUCES CD226 AND T-BET+CD4 T CELLS IN PERIPHERY AND PREVENTS INFILTRATION OF T-BET+ IL-17, IFN-GAMMA PRODUCING T CELLS INTO CNS.PLOS ONE. VOL. 6. ISSUE 7. P. - | 11 | 35% | 4 |
Classes with closest relation at Level 1 |